Sihe Zhang | Medicine | Distinguished Scientist Award

Published on by Scientific World Research Awards

Distinguished Scientist Award

Sihe Zhang
Nankai University, China

Sihe Zhang
Affiliation Nankai University
Country China
Scopus ID 7409373738
Documents 55
Citations 1,269
h-index 16
Subject Area Medicine
Event Scientific World Research Awards
ORCID 0000-0002-8923-1993

The Distinguished Scientist Award recognizes the scholarly achievements of Sihe Zhang, Professor and Director at Nankai University School of Medicine. His research focuses on cancer biology, drug delivery systems, endocytosis, extracellular vesicles, antibody therapeutics, and translational medicine. Through sustained contributions to hepatocellular carcinoma and ovarian cancer research, he has developed innovative approaches that connect molecular mechanisms with therapeutic applications.[1]

Abstract

Sihe Zhang is a biomedical researcher whose work spans cancer biology, antibody engineering, cellular uptake mechanisms, extracellular vesicle biology, and targeted therapeutic delivery. His investigations have contributed to understanding macropinocytosis, endocytic recycling, tumor progression, and resistance mechanisms in hepatocellular and ovarian cancers. He has also participated in the development of innovative antibody-based therapies and nanomedicine strategies aimed at improving treatment specificity and efficacy. His publication portfolio demonstrates a sustained commitment to translational medical research and interdisciplinary collaboration, supporting advancements in cancer diagnosis, drug delivery, and precision medicine.[1][2]

Keywords

Cancer Biology; Drug Delivery; Endocytosis; Extracellular Vesicles; Antibody Therapeutics; Hepatocellular Carcinoma; Ovarian Cancer; Nanomedicine.

Introduction

Professor Zhang has held academic positions at Nankai University and previously at the Fourth Military Medical University. His career reflects long-term engagement with molecular medicine and cell biology, emphasizing mechanisms that influence cancer progression and treatment response.[1]

Research Profile

His research profile combines laboratory discovery with translational applications. Major themes include cellular trafficking, therapeutic antibodies, tumor microenvironment studies, and targeted delivery platforms designed to improve treatment outcomes in oncology.[1]

Research Contributions

Notable contributions include investigations into CD147-mediated signaling, extracellular vesicle uptake, macropinocytosis-driven drug resistance, and antibody-based cancer therapies. These studies have expanded understanding of tumor biology and therapeutic targeting strategies.[2][3]

Publications

His scholarly record includes 55 indexed publications. Representative works address hepatocellular carcinoma resistance mechanisms, extracellular vesicle biology, peptide delivery systems, anti-CD147 therapeutics, and nanobiotechnology-based treatment approaches.[2][4]

Research Impact

With 1,269 citations and an h-index of 16, his research has influenced studies in cancer therapeutics, molecular oncology, and biomedical engineering. The impact of his work is reflected through citations, collaborations, and peer-review activities across leading journals.[1]

Award Suitability

The breadth of Professor Zhang’s contributions, combined with sustained publication output and translational relevance, aligns with the objectives of the Scientific World Research Awards. His work demonstrates scientific rigor and practical relevance in medicine.[1]

Conclusion

Sihe Zhang has established a recognized research portfolio in cancer biology and therapeutic innovation. His scholarly achievements and ongoing contributions support recognition through the Distinguished Scientist Award.[1]

References

  1. ORCID. (2026). Sihe Zhang (0000-0002-8923-1993) Research Profile.https://orcid.org/0000-0002-8923-1993
  2. Qian, L., et al. (2025). The uptake of extracellular vesicles: Research progress in cancer drug resistance and beyond. Drug Resistance Updates.https://doi.org/10.1016/j.drup.2025.101209
  3. Qi, F.Z., et al. (2024). Hypoxia-activated ADCC-enhanced humanized anti-CD147 antibody. MedComm.https://doi.org/10.1002/mco2.512
  4. Sun, Z., et al. (2023). Cell-Penetrating Peptide-Based Delivery of Macromolecular Drugs. Biomedicines.https://doi.org/10.3390/biomedicines11071971
  5. Wang, B., et al. (2024). Hypoxia-activated selectivity-improved anti-PKM2 antibody combined with prodrug TH-302. International Journal of Biological Sciences.https://doi.org/10.7150/ijbs.92211

Yoshiya Tanaka | Medicine | Innovative Research Award

Published on by Scientific World Research Awards

Innovative Research Award

Yoshiya Tanaka

Yoshiya Tanaka
Affiliation Hospital of University of Occupational and Environmental Health
Country Japan
Scopus ID 56328279400
Documents 1,326
Citations 50,831
h-index 99
Subject Area Medicine
Event Scientific World Research Awards

Yoshiya Tanaka, Hospital of University of Occupational and Environmental Health, Japan, is recognized for substantial contributions to rheumatology, immunology, and autoimmune disease research. His scholarly output, clinical investigations, and leadership in international collaborations have supported advancements in evidence-based medical practice and therapeutic development.[1]

Abstract

The Innovative Research Award recognizes researchers whose work demonstrates sustained scientific excellence and measurable impact. Yoshiya Tanaka has contributed extensively to rheumatology and clinical immunology through studies on autoimmune diseases, inflammatory mechanisms, biologic therapies, and targeted treatments. His research has informed clinical guidelines, improved disease classification systems, and supported the development of therapeutic strategies for conditions such as systemic lupus erythematosus, rheumatoid arthritis, and IgG4-related disease. With a substantial publication record and broad international collaboration, his work has influenced both academic research and patient care, reflecting the objectives of the Scientific World Research Awards.[1][2]

Keywords

Rheumatology, Clinical Immunology, Autoimmune Diseases, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Biologic Therapy, Translational Medicine.

Introduction

Modern rheumatology depends on interdisciplinary research linking immunology, molecular biology, and clinical practice. Yoshiya Tanaka has participated in investigations that enhanced understanding of inflammatory pathways and treatment approaches for immune-mediated diseases.[3]

Research Profile

As Professor and Chairman in rheumatology and clinical immunology, Tanaka has developed a research portfolio focused on disease mechanisms, therapeutic innovation, and clinical trial leadership. His scholarly record reflects long-term engagement with translational medicine and global collaboration.[1]

Research Contributions

Key contributions include studies supporting lupus classification criteria, IgG4-related disease frameworks, Janus kinase inhibitor development, and biologic treatment evaluation. These efforts have contributed to improved disease assessment and therapeutic decision-making.[2][4]

Publications

  • 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus.
  • Trial of Anifrolumab in Active Systemic Lupus Erythematosus.
  • Janus Kinase-Targeting Therapies in Rheumatology.

Research Impact

The researcher’s publications have received extensive citations, demonstrating influence across clinical medicine and immunology. Findings from collaborative studies have informed guidelines, therapeutic development, and evidence-based healthcare practices internationally.[1][5]

Award Suitability

The breadth of scientific output, citation performance, clinical relevance, and leadership in collaborative research aligns with the objectives of the Innovative Research Award. His contributions demonstrate sustained scholarly influence and practical significance in medicine.

Conclusion

Yoshiya Tanaka’s career reflects a consistent commitment to advancing knowledge in rheumatology and autoimmune disease research. His achievements support recognition within international scientific award programs and academic communities.

References

  1. Elsevier. (n.d.). Scopus author details: Yoshiya Tanaka, Author ID 56328279400. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=56328279400
  2. Aringer, M., et al. (2019). 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus.
    DOI: https://doi.org/10.1002/art.40930
  3. Tanaka, Y., Adams, D.H., & Shaw, S. (1993). T-cell Adhesion Induced by Proteoglycan-Immobilized Cytokine MIP-1β.
    DOI: https://doi.org/10.1038/361079a0
  4. Tanaka, Y., Luo, Y., O’Shea, J.J., & Nakayamada, S. (2022). Janus Kinase-Targeting Therapies in Rheumatology.
    DOI: https://doi.org/10.1038/s41584-021-00726-8
  5. Google Scholar. (2026). Yoshiya Tanaka Citation Profile.
    https://scholar.google.com/citations?user=t_hAg7QAAAAJ&hl=en

Philipp Kanske | Medicine | Research Excellence Award

Published on by Scientific World Research Awards

Prof. Dr. Philipp Kanske | Medicine | Research Excellence Award

Professor | TUD Dresden University of Technology | Germany

Prof. Dr. Philipp Kanske is an internationally recognized expert in cognitive and affective neuroscience whose work bridges psychology, social cognition, neuroimaging, and mental health research. His research centers on empathy, compassion, emotion regulation, personality functioning, and the neurobiological mechanisms that shape human social behavior across the lifespan. He investigates how individuals perceive and respond to others’ emotions, how empathic stress is transmitted within families, and how interventions such as meditation and compassion training can induce functional neural plasticity and improve emotional well-being, particularly in older adults. His interests extend to personality organization in both clinical and non-clinical populations, disease progression in bipolar disorder, white-matter microstructure, attachment dynamics in couples, value integration for self and others, and ritual-based methods for strengthening human–nature connectedness in the context of sustainability transformations. Prof. Kanske is skilled in a wide range of methodologies including experimental psychology, behavioral analysis, longitudinal study design, cognitive testing, psychoneuroendocrinology, structural and functional MRI, and advanced statistical modeling. His contributions to research transparency and reproducibility are reflected in his leadership in developing the PECANS methodological framework for cognitive and neuropsychological studies. Throughout his career, he has received multiple awards and honors (as listed in Scopus’s “Awarded Grants” section), recognizing his innovative contributions to social neuroscience, aging research, and clinical psychology. According to Scopus Preview, he has 7,136 citations, 163 documents, and an impressive h-index of 43, underscoring his global scientific influence and sustained scholarly productivity. Overall, Prof. Dr. Philipp Kanske’s work provides significant insights into how emotional, neural, and relational processes shape human behavior, offering important implications for mental health, interpersonal functioning, and societal well-being, and solidifying his role as a leading figure in modern neuroscience and psychology.

Profiles: Scopus | ORCID | Google Scholar

Featured Publications

  1. Kanske, P., Heissler, J., Schönfelder, S., Bongers, A., & Wessa, M. (2011). How to regulate emotion? Neural networks for reappraisal and distraction. Cerebral Cortex, 21(6), 1379–138.
    Citations: 698

  2. Schurz, M., Radua, J., Tholen, M. G., Maliske, L., Margulies, D. S., Mars, R. B., … Kanske, P. (2021). Toward a hierarchical model of social cognition: A neuroimaging meta-analysis and integrative review of empathy and theory of mind. Psychological Bulletin, 147(3), 293–. Citations: 648

  3. Kanske, P., & Kotz, S. A. (2007). Concreteness in emotional words: ERP evidence from a hemifield study. Brain Research, 1148, 138–148. Citations: 630

  4. Preckel, K., Kanske, P., & Singer, T. (2018). On the interaction of social affect and cognition: Empathy, compassion and theory of mind. Current Opinion in Behavioral Sciences, 19, 1–6.
    Citations: 554

  5. Moshontz, H., Campbell, L., Ebersole, C. R., IJzerman, H., Urry, H. L., Forscher, P. S., … Kanske, P. (2018). The Psychological Science Accelerator: Advancing psychology through a distributed collaborative network. Advances in Methods and Practices in Psychological Science, 1(4), 501–515. Citations: 499

Prof. Dr. Philipp Kanske’s work advances global scientific understanding of empathy, compassion, and emotion regulation by uncovering the neural and psychological mechanisms that drive healthy social functioning. His research enables evidence-based mental-health interventions, strengthens human well-being across communities, and supports interdisciplinary innovation in neuroscience, clinical psychology, aging research, and societal resilience.

 

Hengrui Liu | Medicine | Best Researcher Award

Published on by Scientific World Research Awards

Prof. Dr. Hengrui Liu | Medicine | Best Researcher Award

Researcher | University of Cambridge | United Kingdom

Dr. Hengrui Liu is a distinguished researcher at the University of Cambridge, United Kingdom, whose interdisciplinary work spans molecular biology, oncology, pharmacogenomics, and bioinformatics. With a remarkable Scopus h-index of 31, over 2,300 citations, and 55 publications, Dr. Liu has made substantial contributions to understanding cancer biology and translational medicine. His research integrates computational modeling, systems biology, and experimental oncology, focusing on identifying molecular mechanisms underlying drug resistance, tumor progression, and therapeutic targeting.One of Dr. Liu’s notable contributions includes the use of CRISPR screening and cell line IC50 data to uncover genes responsible for trametinib resistance, highlighting potential pathways for targeted cancer therapy. He also explores the role of transcription factors in protein autoubiquitination across multiple cancer types through pan-cancer in-silico profiling, advancing precision oncology approaches. His expertise extends to traditional medicine and integrative therapies, as seen in his recent studies on the role of traditional Chinese medicine (TCM) in improving liver transplantation outcomes, bridging conventional and modern biomedical practices.Dr. Liu’s recent review on the multidimensional role of laminin γ2 (LAMC2) in cancer progression provides a comprehensive understanding of how extracellular matrix components influence tumor behavior and metastasis. His interdisciplinary research brings together molecular mechanisms, clinical relevance, and computational insight, reflecting a holistic approach to biomedical innovation. Moreover, his collaborative network of over 100 co-authors underscores his global impact and leadership in international scientific research.Through his pioneering studies, Dr. Hengrui Liu contributes to the development of novel therapeutic strategies, drug resistance biomarkers, and predictive computational frameworks that enhance the diagnosis, treatment, and prognosis of complex diseases such as cancer. His work exemplifies the synergy between data-driven research and molecular experimentation, reinforcing his reputation as a forward-thinking scientist shaping the future of personalized medicine and biomedical innovation.

Profiles: Scopus | ORCID | Google Scholar

Featured Publications

Liu, H., et al. (2025). CRISPR screening and cell line IC50 data reveal novel key genes for trametinib resistance. Open-access Letter. 26 citations.

Liu, H., et al. (2025). In vitro antibacterial activity of neochebulinic acid from aqueous extract of Terminalia chebula Retz against Helicobacter pylori. BMC Complementary Medicine and Therapies. 1 citation.

Liu, H., et al. (2025). An in-silico pan-cancer bulk and single-cell profiling of transcription factors in protein autoubiquitination. Discover Oncology. 2 citations.

Liu, H., et al. (2025). The multidimensional role of laminin γ2 (LAMC2) on cancer progression. Review Article. 0 citations.

Liu, H., et al. (2025). Role of traditional Chinese medicine in supporting liver transplantation outcomes. World Journal of Transplantation. 4 citations.

Shinichiro Sawa | Medicine | Best Researcher Award

Published on by Scientific World Research Awards

Dr. Shinichiro Sawa | Medicine | Best Researcher Award

Professor | Kyushu University | Japan 

Dr. Shinichiro Sawa is a highly accomplished Japanese immunologist and medical researcher renowned for his pioneering work in immune regulation, autoimmunity, and inflammation. He currently serves as a Professor at the Institute of Bioregulation, Kyushu University, Japan, where he leads innovative studies in molecular and cellular immunology. Dr. Sawa began his academic journey at Osaka University, earning his Medical Degree (M.D.) in 2000 and subsequently his Ph.D. in Medicine in 2006 from the same institution, where he developed a strong foundation in biomedical sciences and experimental medicine. His professional trajectory includes significant academic roles as Assistant Professor at the University of Tokyo (2011–2016) and Associate Professor at Hokkaido University’s Institute for Genetic Medicine (2016–2018) before joining Kyushu University in 2019. Dr. Sawa’s research interests center on understanding how immune cells, such as γδ T cells, fibroblasts, and plasma cells, interact with tissue environments to regulate immune tolerance, autoimmunity, and inflammatory diseases. His studies, published in prestigious journals such as Nature Immunology, Journal of Clinical Investigation, and Journal of Investigative Dermatology, have shed light on how fibroblasts contribute to central immune tolerance and how plasma cells promote osteoclastogenesis in autoimmune arthritis. His research skills encompass cellular immunology, molecular signaling analysis, animal modeling of immune diseases, flow cytometry, and translational immunopathology, demonstrating both depth and precision in experimental design and interpretation. Recognized for his scientific contributions, Dr. Sawa has received numerous academic honors and research recognitions throughout his career, reflecting his influence in the global immunology community. In conclusion, Dr. Shinichiro Sawa stands as a leading figure in immunological research, bridging basic science and clinical application to advance our understanding of immune homeostasis and to pave the way for novel therapeutic strategies against autoimmune and inflammatory disorders.

Profiles: Scopus | ORCID

Featured Publications

  1. Nonaka, D., Yoshida, S., Nakano, K., Li, X., Okamura, T., Umemoto, E., Yamada, T., Watanabe, M., Jinno, S., Ito, M., Tsuda, M., Noguchi, N., Jiang, X.-J., Sumiya, E., & Sawa, S. (2025). Fibroblast-derived CSF1 maintains colonization of gut mucosal macrophage to resist bacterial infection. Mucosal Immunology.

  2. Onji, M., Sigl, V., Lendl, T., Novatchkova, M., Ullate-Agote, A., Andersson-Rolf, A., Kozieradzki, I., Koglgruber, R., Pai, T.-P., Lichtscheidl, D., Nayak, K., Zilbauer, M., Carranza García, N.-A., Sievers, L., Falk-Paulsen, M., Cronin, S. J. F., Hagelkruys, A., Sawa, S., Osborne, L. C., Rosenstiel, P., Pasparakis, M., Ruland, J., Takayanagi, H., Clevers, H., Koo, B.-H., & Penninger, J. M. (2025). RANK drives structured intestinal epithelial expansion during pregnancy. Nature, 637(8044), 156–166.

  3. Nitta, T., Tsutsumi, M., Nitta, S., Muro, R., Suzuki, E. C., Nakano, K., Tomofuji, Y., Sawa, S., Okamura, T., Penninger, J. M., & Takayanagi, H. (2020). Fibroblasts as a source of self-antigens for central immune tolerance. Nature Immunology, 21(10), 1172–1180.

  4. Nagashima, K., Sawa, S., Nitta, T., Tsutsumi, M., Okamura, T., Penninger, J. M., Nakashima, T., & Takayanagi, H. (2017). Identification of subepithelial mesenchymal cells that induce IgA and diversify gut microbiota. Nature Immunology, 18(6), 675–682.

  5. Onder, L., Mörbe, U., Pikor, N., Novkovic, M., Cheng, H.-W., Hehlgans, T., Pfeffer, K., Becher, B., Waisman, A., Rülicke, T., Gommerman, J., Müller, C., Sawa, S., Scandella, E., & Ludewig, B. (2017). Lymphatic endothelial cells control initiation of lymph node organogenesis. Immunity, 47(1), 80–92.

 

Hugh Sampson | Medicine | Best Researcher Award

Published on by Scientific World Research Awards

Dr. Hugh Sampson | Medicine | Best Researcher Award

Professor of Pediatrics | Icahn School of Medicine at Mount Sinai | United States

Dr. Hugh A. Sampson, MD, is a distinguished physician-scientist and pediatric immunologist best known for his pioneering contributions in food allergy and immunopathogenesis, and is currently the Kurt Hirschhorn Professor of Pediatrics and Director Emeritus of the Jaffe Food Allergy Institute at the Icahn School of Medicine at Mount Sinai. He earned a B.A. in Biology from Hamilton College in 1971, then obtained his M.D. from SUNY Buffalo in 1975, followed by a pediatric residency at Northwestern University / Children’s Memorial Hospital and an allergy/immunology fellowship at Duke University (1978–1980). Over his career, he has held leadership roles including chairing the Section on Allergy & Immunology of the American Academy of Pediatrics, serving as past President of AAAAI, holding editorial board positions in leading allergy/immunology journals, and directing national food allergy research consortia. His research interests encompass the pathogenesis of food-induced anaphylaxis, the molecular and immunologic characterization of allergenic food proteins and epitopes, genetics and immune regulation in food allergy, development of precision diagnostics (e.g. epitope-specific IgE/IgG4 profiles), and immunotherapy strategies (oral, epicutaneous, sublingual, and biologics such as anti-IgE) as well as novel therapeutic approaches. His research skills include translational and clinical trial design, immunologic assays (e.g. epitope mapping, serologic biomarkers), mechanistic in vitro and in vivo models, bioinformatics integration, large cohort epidemiologic and registry studies, and mentoring interdisciplinary teams. Among his many awards and honors are election to the National Academy of Medicine (Institute of Medicine) in 2003, the Brett Ratner Award from the American Academy of Pediatrics, the Distinguished Scientist Award of AAAAI, memberships in honorary societies (Alpha Omega Alpha, Sigma Xi), and repeated recognitions from Research.com as a top immunology scientist. According to his institutional profile, his h-index (based on Scopus/Pure) is listed at ~85,982 (which appears anomalous and may reflect internal counting metrics), while bibliometric sources more conservatively report an h-index of ~147 with over 800+ publications; traditional citation counts exceed 100,000 across his work. In conclusion, Dr. Sampson’s career exemplifies a remarkable integration of basic immunology and clinical translation: his leadership, mentorship, and sustained high-impact scholarship have shaped the modern field of food allergy research, spawning diagnostic and therapeutic innovations and training generations of investigators in allergy and immunology.

Profiles: Scopus | ORCID 

Featured Publications

  1. Rose, N. R., Milisauskas, V., & Sampson, H. A. (1975). Species-specific tissue antigens. III. Immunological relationships of enzymic antigens in various species. Clinical and Experimental Immunology, 20, 359–370.

  2. Sampson, H. A., & Buckley, R. H. (1981). Human IgE synthesis in vitro: A reassessment. Journal of Immunology, 127, 829–834.

  3. Rich, K. C., Sampson, H. A., Edwards, N. L., & Fox, I. H. (1981). Familial hypogammaglobulinemia with variable serum immunoglobulins: Concordance with lymphocyte ecto-5′-nucleotidase deficiency. American Journal of Diseases of Children, 135, 795–798.

  4. Sampson, H. A., Walchner, A., & Baker, P. (1981). Recurrent pyogenic infections in individuals with absence of the second component of complement. Journal of Clinical Immunology, 2, 39–45.

  5. LoGalbo, P. R., Sampson, H. A., & Buckley, R. H. (1982). Symptomatic giardiasis in three patients with X-linked agammaglobulinemia. Journal of Pediatrics, 101, 78–80.